# Evidium

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evidium

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.evidium.com
- Total disclosed funding: $22M
- Latest round: Series A (Nov 10, 2025)
- Investors on record: 6

## About

Evidium, Inc., based in the US, specializes in neurosymbolic artificial intelligence to enhance healthcare decision-making, transforming medical knowledge into actionable intelligence for improved patient outcomes.Founded in 2023 and headquartered in San Francisco, US, Evidium, Inc. focuses on integrating fragmented healthcare data to facilitate informed clinical decision-making. In November 2025, the company raised USD 22 mn in Series A funding, co-led by Health2047 Capital Partners and WGG Partners, with participation from Interwoven Ventures and Mindset Ventures. The company has completed a single funding round to date, raising a total of USD 22 mn.Evidium enhances healthcare decision-making with its innovative reasoning platform, integrating diverse medical data to map clinical journeys according to medical guidelines and real-world evidence. Its primary clientele includes self-insured stakeholders, insurers, health systems, clinicians, and providers, aiming to improve quality metrics in clinical workflows. The platform is marketed mainly in the United States, with plans for future expansion into life sciences sectors.Evidium generates revenue through a subscription-based model, allowing clients continuous access to its reasoning platform, which is often integrated into existing health systems. While specific pricing plans are undisclosed, the focus remains on long-term contracts and service agreements, ensuring a steady income as clients leverage the platform's capabilities for improved healthcare outcomes.With the recent funding of USD 22 mn raised in November 2025, Evidium plans to accelerate product development and strengthen its clinical modeling capabilities. The company aims to expand its go-to-market operations and hire specialists in AI research, clinical science, and business development. These initiatives are designed to support the launch of upcoming products and further penetrate specific markets, particularly in the life sciences sector.

## Funding rounds

- Series A, Nov 10, 2025, $22M — Mindset Ventures, Health2047 Capital Partners, WGG Partners, Perplexity AI, Inc., X.AI Corp., Interwoven Ventures

## Investors

- Mindset Ventures (https://capitalatlas.ai/funds/mindset-ventures) — Series A
- Health2047 Capital Partners (https://capitalatlas.ai/funds/health2047-capital-partners) — Series A
- WGG Partners — Series A
- Perplexity AI, Inc. — Series A
- X.AI Corp. — Series A
- Interwoven Ventures (https://capitalatlas.ai/funds/interwoven-ventures) — Series A